{"groups":[{"description":"Patients with relapsed multiple myeloma receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\ncyclophosphamide: Given IV or PO\n\npegylated liposomal doxorubicin hydrochloride: Given IV\n\nbortezomib: Given IV\n\ndexamethasone: Given IV or PO","id":"FG000","title":"Relapsed Disease (Cohort I)"},{"description":"Patients with newly diagnosed multiple myeloma receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\ncyclophosphamide: Given IV or PO\n\npegylated liposomal doxorubicin hydrochloride: Given IV\n\nbortezomib: Given IV\n\ndexamethasone: Given IV or PO","id":"FG001","title":"Newly Diagnosed Disease (Cohort II)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}